We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Moves -1.13%: What You Should Know
Read MoreHide Full Article
In the latest market close, Gilead Sciences (GILD - Free Report) reached $78.59, with a -1.13% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.47%. Meanwhile, the Dow experienced a drop of 1.27%, and the technology-dominated Nasdaq saw a decrease of 1.5%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 6.43% over the past month, outpacing the Medical sector's gain of 5.51% and the S&P 500's gain of 5.77% in that time.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. In that report, analysts expect Gilead Sciences to post earnings of $1.78 per share. This would mark year-over-year growth of 6.59%. Simultaneously, our latest consensus estimate expects the revenue to be $7.07 billion, showing a 4.26% drop compared to the year-ago quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.74 per share and revenue of $27.08 billion. These results would represent year-over-year changes of -7.16% and -0.75%, respectively.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.21% fall in the Zacks Consensus EPS estimate. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, Gilead Sciences is currently being traded at a Forward P/E ratio of 11.8. This indicates a discount in contrast to its industry's Forward P/E of 17.31.
We can also see that GILD currently has a PEG ratio of 1.04. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.87 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 64, positioning it in the top 26% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Moves -1.13%: What You Should Know
In the latest market close, Gilead Sciences (GILD - Free Report) reached $78.59, with a -1.13% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.47%. Meanwhile, the Dow experienced a drop of 1.27%, and the technology-dominated Nasdaq saw a decrease of 1.5%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 6.43% over the past month, outpacing the Medical sector's gain of 5.51% and the S&P 500's gain of 5.77% in that time.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. In that report, analysts expect Gilead Sciences to post earnings of $1.78 per share. This would mark year-over-year growth of 6.59%. Simultaneously, our latest consensus estimate expects the revenue to be $7.07 billion, showing a 4.26% drop compared to the year-ago quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.74 per share and revenue of $27.08 billion. These results would represent year-over-year changes of -7.16% and -0.75%, respectively.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.21% fall in the Zacks Consensus EPS estimate. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, Gilead Sciences is currently being traded at a Forward P/E ratio of 11.8. This indicates a discount in contrast to its industry's Forward P/E of 17.31.
We can also see that GILD currently has a PEG ratio of 1.04. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.87 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 64, positioning it in the top 26% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.